Skip to main content

Articles

Practice Management
New Value Model Incorporates Long-Term Adverse Effects of Cancer Drugs
Read More
Multiple Myeloma, Oncology
HIV Drug Shows Promise in Refractory Multiple Myeloma
Read More
Multiple Myeloma, Oncology
Venetoclax plus Bortezomib and Dexamethasone Produces High Responses in Patients with Relapsed or Refractory Multiple Myeloma
Read More
Pacritinib Shows Good Efficacy in Myelofibrosis: Will the FDA Release Hold on the Drug?
Read More
Lymphoma
Brentuximab Vedotin Improves Responses Lasting 4 Months in Cutaneous T-Cell Lymphoma
Read More
Leukemia, Oncology
Chemotherapy-Free Induction with Ibrutinib plus Rituximab Shows Unprecedented Efficacy in MCL
Read More
Lymphoma
Pembrolizumab Produces Durable Responses in Relapsed or Refractory Cutaneous T-Cell Lymphoma
Read More
Lymphoma
R-CHOP Prevails Over Dose-Adjusted EPOCH-R as Standard of Care for Diffuse Large B-Cell Lymphoma
Read More
FDA Approvals
Novel Hypomethylating Agent Active in Patients with High-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
Read More
FDA Approvals
Glasdegib, a Hedgehog Inhibitor, Nearly Doubles Survival in AML or High-Risk MDS
Read More
Page 97 of 245
Results 961 - 970 of 2441